Bellew Shawna D, Johnson Katie L, Nichols Micah D, Kummer Tobias
Department of Emergency Medicine, Vanderbilt University, Nashville, Tennessee; VA National Quality Scholars Program, VA Tennessee Valley Healthcare System, Nashville, Tennessee.
Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota.
J Emerg Med. 2018 Oct;55(4):455-464. doi: 10.1016/j.jemermed.2018.07.004. Epub 2018 Sep 6.
Treatment for epistaxis includes application of intranasal vasoconstrictors. These medications have a precaution against use in patients with hypertension. Given that many patients who present with epistaxis are hypertensive, these warnings are commonly overridden by clinical necessity.
Our aim was to determine the effects of intranasal vasoconstrictors on blood pressure.
We conducted a single-center, randomized, double-blind, placebo-controlled trial from November 2014 through July 2016. Adult patients being discharged from the emergency department (ED) at Mayo Clinic (Rochester, Minnesota) were recruited. Patients were ineligible if they had a contraindication to study medications, had a history of hypertension, were currently taking antihypertensive or antidysrhythmic medications, or had nasal abnormalities, such as epistaxis. Subjects were randomized to one of four study arms (phenylephrine 0.25%; oxymetazoline 0.05%; lidocaine 1% with epinephrine 1:100,000; or bacteriostatic 0.9% sodium chloride [saline]). Blood pressure and heart rate were measured every 5 min for 30 min.
Sixty-eight patients were enrolled in the study; of these, 63 patients completed the study (oxymetazoline, n = 15; phenylephrine, n = 20; lidocaine with epinephrine, n = 11; saline, n = 17). We did not observe any significant differences in mean arterial pressure over time between phenylephrine and saline, oxymetazoline and saline, or lidocaine with epinephrine and saline. The mean greatest increases from baseline in mean arterial pressure, systolic and diastolic blood pressure, and heart rate for each treatment group were also not significantly different from the saline group.
Intranasal vasoconstrictors did not significantly increase blood pressure in patients without a history of hypertension. Our findings reinforce the practice of administering these medications to patients who present to the ED with epistaxis, regardless of high blood pressure.
鼻出血的治疗方法包括使用鼻内血管收缩剂。这些药物对高血压患者的使用有预防措施。鉴于许多鼻出血患者患有高血压,出于临床需要,这些警告通常被忽视。
我们的目的是确定鼻内血管收缩剂对血压的影响。
我们于2014年11月至2016年7月进行了一项单中心、随机、双盲、安慰剂对照试验。招募了从梅奥诊所(明尼苏达州罗切斯特)急诊科出院的成年患者。如果患者有研究药物的禁忌症、有高血压病史、目前正在服用抗高血压或抗心律失常药物,或有鼻出血等鼻腔异常情况,则不符合入选标准。受试者被随机分配到四个研究组之一(0.25%去氧肾上腺素;0.05%羟甲唑啉;1%利多卡因加1:100,000肾上腺素;或抑菌0.9%氯化钠[生理盐水])。每隔5分钟测量一次血压和心率,共测量30分钟。
68名患者参加了该研究;其中,63名患者完成了研究(羟甲唑啉组,n = 15;去氧肾上腺素组,n = 20;利多卡因加肾上腺素组,n = 11;生理盐水组,n = 17)。我们没有观察到去氧肾上腺素与生理盐水、羟甲唑啉与生理盐水、或利多卡因加肾上腺素与生理盐水之间平均动脉压随时间的任何显著差异。每个治疗组平均动脉压、收缩压和舒张压从基线的最大平均升高以及心率与生理盐水组相比也没有显著差异。
鼻内血管收缩剂在无高血压病史的患者中不会显著升高血压。我们的研究结果支持了对因鼻出血就诊于急诊科的患者使用这些药物的做法,无论其是否患有高血压。